MX
MXCT.US MaxCyte Inc
- Market cap
- USD 123M
- P/E
- -
- P/B
- 0.81x
- ROE
- -16.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MXCT.US undervalued?
Graham numberThe Graham number of MaxCyte Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MaxCyte Inc fundamental analysis
No fundamental analysis for MaxCyte Inc yet.
MaxCyte Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in t…
Full company profileMaxCyte Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MaxCyte Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.3M | 14.0M | 16.7M | 21.6M | 26.2M | 33.9M | 44.3M | 41.3M | 38.6M | 33.0M | 36.1M |
| Gross Profit | 11.0M | 12.5M | 14.8M | 19.1M | 23.4M | 30.2M | 39.2M | 36.5M | 31.5M | 26.8M | 28.2M |
| Operating Income | -2.72M | -9.29M | -8.42M | -12.4M | -11.1M | -18.2M | -27.4M | -48.3M | -51.2M | -45.3M | -29.9M |
| EBITDA | -2.60M | -9.15M | -7.91M | -11.6M | -9.94M | -16.6M | -20.7M | -33.4M | -36.7M | -39.5M | -20.4M |
| Net Income | -3.35M | -9.92M | -8.87M | -12.9M | -11.8M | -19.1M | -23.6M | -37.9M | -41.1M | -44.6M | -24.5M |
| EPS | -0.10 | -0.20 | -0.17 | -0.23 | -0.17 | -0.21 | -0.23 | -0.37 | -0.39 | -0.42 | -0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 16.1M | 31.4M | 24.3M | 30.0M | 51.8M | 284M | 287M | 268M | 239M | 203M | 182M |
| Total Liabilities | 11.0M | 11.8M | 12.0M | 16.4M | 18.6M | 21.2M | 32.7M | 36.1M | 33.2M | 31.0M | 31.6M |
| Shareholders' Equity | 5.08M | 19.6M | 12.3M | 13.6M | 33.2M | 263M | 254M | 232M | 206M | 171M | 151M |
| Cash & Short-term Investments | 11.7M | 25.3M | 14.4M | 16.7M | 34.8M | 255M | 227M | 168M | 154M | 103M | 101M |
| Total Debt | 5.01M | 5.03M | 5.06M | 7.21M | 6.97M | 5.68M | 16.1M | 18.7M | 18.0M | 17.9M | 16.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.34M | -9.68M | -10.5M | -8.80M | -8.78M | -10.7M | -14.8M | -21.7M | -27.6M | -34.4M | -24.4M |
| Capital Expenditure | 219K | 610K | 710K | 1.27M | 2.07M | 3.83M | 18.5M | 3.70M | 1.65M | 1.77M | 457K |
| Free Cash Flow | -2.55M | -10.3M | -11.2M | -10.1M | -10.9M | -14.5M | -33.3M | -25.4M | -29.3M | -36.2M | -24.9M |
| Ratios | |||||||||||
| ROE | -65.8% | -50.6% | -72.2% | -94.8% | -35.6% | -7.3% | -9.3% | -16.3% | -19.9% | -26.0% | -16.2% |
| ROA | -20.8% | -31.6% | -36.5% | -43.0% | -22.8% | -6.7% | -8.2% | -14.1% | -17.1% | -22.0% | -13.4% |
| Net Profit Margin | -27.3% | -70.9% | -53.2% | -59.6% | -45.2% | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% | -67.9% |
| Debt to Equity | 0.98x | 0.26x | 0.41x | 0.53x | 0.21x | 0.02x | 0.06x | 0.08x | 0.09x | 0.10x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MaxCyte Inc dividends
MaxCyte Inc has not paid dividends in the last 9 fiscal years.
Who owns MaxCyte Inc
- Insiders 1.84%
- Institutions 65.83%
- Public & others 32.34%
- Shares outstanding 103M
- Free float 93.7M
Top funds holding MXCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AXA Framlington Health Fund - R Income | 2.77M | 2.60% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.74M | 2.57% | 0.00% | Sep 2026 |
| Liontrust UK Listed Smaller Coms B Acc | 2.73M | 2.55% | -28.29% | Jul 2026 |
| Unicorn AIM VCT Ord | 2.49M | 2.33% | 0.00% | Oct 2026 |
| Liontrust Instl UK Lstd Smlr Coms P Acc | 1.75M | 1.64% | 0.00% | Jul 2026 |
| River UK Micro Cap Ord | 834K | 0.78% | 0.00% | Jun 2026 |
| MI Chelverton UK Equity Growth B Acc | 700K | 0.66% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 493K | 0.46% | -10.70% | Sep 2026 |
| Morgan Stanley Inst Inception I | 347K | 0.33% | 0.00% | Jun 2026 |
| EQ/Morgan Stanley Small Cap Growth K | 288K | 0.27% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 284K | 0.27% | +0.11% | Sep 2026 |
| Fidelity Total Market Index | 199K | 0.19% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 171K | 0.16% | 0.00% | Sep 2026 |
| Liontrust UK Recovery B Inc | 156K | 0.15% | +14.48% | Jul 2026 |
| Schwab Total Stock Market Index | 115K | 0.11% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 109K | 0.10% | +172.14% | Jun 2026 |
| Pacific Select Large-Cap Growth I | 106K | 0.10% | 0.00% | Oct 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 75.7K | 0.07% | 0.00% | Sep 2026 |
| BlackRock Diversified Equity Alpha Inst | 74.4K | 0.07% | 0.00% | Jul 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 58.8K | 0.06% | 0.00% | Oct 2026 |
Top institutions holding MXCT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8.20M | 7.68% | 0.00% | Jun 2026 |
| Vitruvian Partners | 5.04M | 4.72% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.03M | 3.78% | +1.24% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.69M | 3.46% | +0.16% | Jun 2026 |
| Mudita Advisors LLP | 3.37M | 3.16% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.06M | 2.87% | -65.21% | Jun 2026 |
| Brooklands Fund Management Limited | 2.85M | 2.67% | +30.05% | Jun 2026 |
| BNP Paribas Investment Partners SA | 2.77M | 2.60% | 0.00% | Jun 2026 |
| Cadian Capital Management LP | 2.20M | 2.06% | +27.76% | Jun 2026 |
| Peapod Lane Capital LLC | 2.13M | 1.99% | +59.57% | Jun 2026 |
| Renaissance Technologies Corp | 2.04M | 1.91% | +6.52% | Sep 2026 |
| AQR Capital Management LLC | 1.88M | 1.76% | +54.18% | Jun 2026 |
| Jane Street Group LLC | 1.56M | 1.46% | +7,498.83% | Jun 2026 |
| Two Sigma Investments LLC | 1.46M | 1.37% | +140.55% | Jun 2026 |
| Geode Capital Management, LLC | 1.33M | 1.24% | -43.84% | Jun 2026 |
| RBF LLC | 1.32M | 1.24% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.24M | 1.16% | +7.15% | Jun 2026 |
| Millennium Management LLC | 1.20M | 1.13% | +2,698.30% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 1.20M | 1.12% | +20.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.01M | 0.95% | +925.94% | Jun 2026 |
MaxCyte Inc company profile
- Company name
- MaxCyte Inc
- Ticker
- MXCT.US
- Exchange
- USA Stocks
- Listed since
- Jul 30, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 91
- Fiscal year end
- December
- Address
- 9713 Key West Avenue, Rockville, MD, United States, 20850
- Phone
- 301 944 1700
- Website
- maxcyte.com
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MaxCyte Inc management
6- Mr. Maher MasoudPresident, CEO & Executive Director · born 1976
- Mr. Parmeet AhujaChief Financial Officer · born 1969
- Mr. Jay GelfmanChief Operations Officer
- Ms. Ana-Paula Martins FernandesSenior Vice President of Global Sales
- Mr. Sidharth KapileshwarChief Corporate Development Officer
- Ms. Jill MayerSenior Vice President of Human Resources